دسترسی یکساله به بیش از ۵۰۰ ژورنال روز جهان موجود در سامانه
-
http://medilib.ir
- ﻣﺪﺕ ﺯﻣﺎﻥ : 365 ﺭﻭﺯ
قیمت : 3,800,000 تومان- قیمت ویژه : 1,900,000تومان
Cardio-Protective Therapy in Cardio-Oncology: Quo Vadis?
Torbjørn Omland
doi : 10.1161/CIRCULATIONAHA.121.055541
Circulation. 2021;144:667–669
Pravastatin Versus Placebo in Pregnancies at High Risk of Term Preeclampsia
Moritz Döbert, Anna Nektaria Varouxaki, An Chi Mu, Argyro Syngelaki, Anca Ciobanu, Ranjit Akolekar, Catalina De Paco Matallana, Simona Cicero, Elena Greco, Mandeep Singh, Deepa Janga, Maria del Mar Gil, Jacques C. Jani, José Luis Bartha, Kate Maclagan, David Wright, Kypros H. Nicolaides
doi : 10.1161/CIRCULATIONAHA.121.053963
Circulation. 2021;144:670–679
Effective screening for term preeclampsia is provided by a combination of maternal factors with measurements of mean arterial pressure, serum placental growth factor, and serum soluble fms-like tyrosine kinase-1 at 35 to 37 weeks of gestation, with a detection rate of ?75% at a screen-positive rate of 10%. However, there is no known intervention to reduce the incidence of the disease.
Challenging Statin Pleiotropy: Preeclampsia
Janet Wei, James K. Liao, C. Noel Bairey Merz
doi : 10.1161/CIRCULATIONAHA.121.056140
Circulation. 2021;144:680–683
Effects of Exercise and Weight Loss on Proximal Aortic Stiffness in Older Adults With Obesity
Tina E. Brinkley, Iris Leng, Margie J. Bailey, Denise K. Houston, Christina E. Hugenschmidt, Barbara J. Nicklas, W. Gregory Hundley
doi : 10.1161/CIRCULATIONAHA.120.051943
Circulation. 2021;144:684–693
Obesity may accelerate age-related increases in aortic stiffness. Although aerobic exercise training generally has favorable effects on aortic structure and function, exercise alone may not be sufficient to improve aortic stiffness in older adults with obesity. We determined the effects of aerobic exercise training with and without moderate- to high-caloric restriction (CR) on the structure and function of the proximal aorta in 160 older (65–79 years) men and women with obesity (body mass index=30–45 kg/m2).
Targeting E3 Ubiquitin Ligase WWP1 Prevents Cardiac Hypertrophy Through Destabilizing DVL2 via Inhibition of K27-Linked Ubiquitination
Dingsheng Zhao, Guohui Zhong, Jianwei Li, Junjie Pan, Yinlong Zhao, Hailin Song, Weijia Sun, Xiaoyan Jin, Yuheng Li, Ruikai Du, Jielin Nie, Tong Liu, Junmeng Zheng, Yixin Jia, Zifan Liu, Wei Liu, Xinxin Yuan, Zizhong Liu, Jinping Song, Guanghan Kan, Youyou Li, Caizhi Liu, Xingcheng Gao, Wenjuan Xing, Yan-Zhong Chang, Yingxian Li, Shukuan Ling
doi : 10.1161/CIRCULATIONAHA.121.054827
Circulation. 2021;144:694–711
Without adequate treatment, pathological cardiac hypertrophy induced by sustained pressure overload eventually leads to heart failure. WWP1 (WW domain–containing E3 ubiquitin protein ligase 1) is an important regulator of aging-related pathologies, including cancer and cardiovascular diseases. However, the role of WWP1 in pressure overload–induced cardiac remodeling and heart failure is yet to be determined.
PKM1 Exerts Critical Roles in Cardiac Remodeling Under Pressure Overload in the Heart
Qinfeng Li, Chao Li, Abdallah Elnwasany, Gaurav Sharma, Yu A. An, Guangyu Zhang, Waleed M. Elhelaly, Jun Lin, Yingchao Gong, Guihao Chen, Meihui Wang, Shangang Zhao, Chongshan Dai, Charles D. Smart, Juan Liu, Xiang Luo, Yingfeng Deng, Lin Tan, Shuang-Jie Lv, Shawn M. Davidson, Jason W. Locasale, Philip L. Lorenzi, Craig R. Malloy, Thomas G. Gillette, Matthew G. Vander Heiden, Philipp E. Scherer, Luke I. Szweda, Guosheng Fu, Zhao V. Wang
doi : 10.1161/CIRCULATIONAHA.121.054885
Circulation. 2021;144:712–727
Metabolic remodeling precedes most alterations during cardiac hypertrophic growth under hemodynamic stress. The elevation of glucose utilization has been recognized as a hallmark of metabolic remodeling. However, its role in cardiac hypertrophic growth and heart failure in response to pressure overload remains to be fully illustrated. Here, we aimed to dissect the role of cardiac PKM1 (pyruvate kinase muscle isozyme 1) in glucose metabolic regulation and cardiac response under pressure overload.
Saphenous Vein Graft Failure: From Pathophysiology to Prevention and Treatment Strategies
Iosif Xenogiannis, Marco Zenati, Deepak L. Bhatt, Sunil V. Rao, Josep Rodés-Cabau, Steven Goldman, Kendrick A. Shunk, Kreton Mavromatis, Subhash Banerjee, Khaldoon Alaswad, Ilias Nikolakopoulos, Evangelia Vemmou, Judit Karacsonyi, Dimitrios Alexopoulos, M. Nicholas Burke, Vinayak N. Bapat, Emmanouil S. Brilakis
doi : 10.1161/CIRCULATIONAHA.120.052163
Circulation. 2021;144:728–745
Saphenous vein grafts (SVGs) remain the most frequently used conduits in coronary artery bypass graft surgery (CABG). Despite advances in surgical techniques and pharmacotherapy, SVG failure rates remain high, often leading to repeat coronary revascularization. The no-touch SVG harvesting technique (minimal graft manipulation with preservation of vasa vasorum and nerves) reduces the risk of SVG failure, whereas the effect of the off-pump technique on SVG patency remains unclear. Use of buffered storage solutions, intraoperative graft flow measurement, careful selection of the target vessels, and physiological assessment of the native coronary circulation before CABG may also reduce the incidence of SVG failure. Perioperative aspirin and high-intensity statin administration are the cornerstones of secondary prevention after CABG. Dual antiplatelet therapy is recommended for off-pump CABG and in patients with a recent acute coronary syndrome. Intermediate (30%–60%) SVG stenoses often progress rapidly. Stenting of intermediate SVG stenoses failed to improve outcomes; hence, treatment focuses on strict control of coronary artery disease risk factors. Redo CABG is associated with higher perioperative mortality compared with percutaneous coronary intervention (PCI); hence, the latter is preferred for most patients requiring repeat revascularization after CABG. SVG PCI is limited by high rates of no-reflow and a high incidence of restenosis during follow-up. Drug-eluting and bare metal stents provide similar long-term outcomes in SVG PCI. Embolic protection devices reduce no-reflow and should be used when feasible. PCI of the corresponding native coronary artery is associated with better short- and long-term outcomes and is preferred over SVG PCI, if technically feasible.
Highlights From the Circulation Family of Journals
doi : 10.1161/CIRCULATIONAHA.121.056713
Circulation. 2021;144:746–750
Not All Waves Are Factual
Gunaseelan Rajendran, Anas Mohammed Muthanikkatt, Balamurugan Nathan
doi : 10.1161/CIRCULATIONAHA.121.055522
Circulation. 2021;144:751–753
New Variant With a Previously Unrecognized Mechanism of Pathogenicity in Hypertrophic Cardiomyopathy
Yasmine Aguib, Mona Allouba, Roddy Walsh, Ayman M. Ibrahim, Sarah Halawa, Alaa Afify, Mohammed Hosny, Pantazis I. Theotokis, Aya Galal, Sara Elshorbagy, Mohamed Roshdy, Heba S. Kassem, Amany Ellithy, Rachel Buchan, Nicola Whiffin, Shehab Anwer, Stuart A. Cook, Ahmed Moustafa, Ahmed ElGuindy, James S. Ware, Paul J.R. Barton, Magdi Yacoub
doi : 10.1161/CIRCULATIONAHA.120.048295
Circulation. 2021;144:754–757
Letter by Hwang et al Regarding Article, “Temporal Release of High-Sensitivity Cardiac Troponin T and I and Copeptin After Brief Induced Coronary Artery Balloon Occlusion in Humans”
Peter Hwang, Richard Schulz, Peter Kavsak
doi : 10.1161/CIRCULATIONAHA.121.055413
Circulation. 2021;144:e166–e167
Letter by Sandoval and Jaffe Regarding Article, “Temporal Release of High-Sensitivity Cardiac Troponin T and I and Copeptin After Brief Induced Coronary Artery Balloon Occlusion in Humans”
Yader Sandoval, Allan S. Jaffe
doi : 10.1161/CIRCULATIONAHA.121.054861
Circulation. 2021;144:e168
Response by Hasselbalch et al to Letter Regarding Article, “Temporal Release of High-Sensitivity Cardiac Troponin T and I and Copeptin After Brief Induced Coronary Artery Balloon Occlusion in Humans”
Rasmus Bo Hasselbalch, Henning Bundgaard, Kasper Karmark Iversen
doi : 10.1161/CIRCULATIONAHA.121.055682
Circulation. 2021;144:e169–e170
Lower Extremity Peripheral Artery Disease: Contemporary Epidemiology, Management Gaps, and Future Directions: A Scientific Statement From the American Heart Association
Michael H. Criqui, Kunihiro Matsushita, Victor Aboyans, Connie N. Hess, Caitlin W. Hicks, Tak W. Kwan, Mary M. McDermott, Sanjay Misra, Francisco Ujueta, and on behalf of the American Heart Association Council on Epidemiology and Prevention; Council on Arteriosclerosis, Thrombosis and Vascular Biology; Council on Cardiovascular Radiology and Intervention; Council on Lifestyle and Cardiometabolic Health; Council on Peripheral Vascular Disease; and Stroke Council
doi : 10.1161/CIR.0000000000001005
Circulation. 2021;144:e171–e191
Lower extremity peripheral artery disease (PAD) affects >230 million adults worldwide and is associated with increased risk of various adverse clinical outcomes (other cardiovascular diseases such as coronary heart disease and stroke and leg outcomes such as amputation). Despite its prevalence and clinical importance, PAD has been historically underappreciated by health care professionals and patients. This underappreciation seems multifactorial (eg, limited availability of the first-line diagnostic test, the ankle-brachial index, in clinics; incorrect perceptions that a leg vascular disease is not fatal and that the diagnosis of PAD would not necessarily change clinical practice). In the past several years, a body of evidence has indicated that these perceptions are incorrect. Several studies have consistently demonstrated that many patients with PAD are not receiving evidence-based therapies. Thus, this scientific statement provides an update for health care professionals regarding contemporary epidemiology (eg, prevalence, temporal trends, risk factors, and complications) of PAD, the present status of diagnosis (physiological tests and imaging modalities), and the major gaps in the management of PAD (eg, medications, exercise therapy, and revascularization). The statement also lists key gaps in research, clinical practice, and implementation related to PAD. Orchestrated efforts among different parties (eg, health care providers, researchers, expert organizations, and health care organizations) will be needed to increase the awareness and understanding of PAD and improve the diagnostic approaches, management, and prognosis of PAD.
Correction to: Prevention of Viridans Group Streptococcal Infective Endocarditis: A Scientific Statement From the American Heart Association
doi : 10.1161/CIR.0000000000001012
Circulation. 2021;144:e192
Correction to: Lower Extremity Peripheral Artery Disease: Contemporary Epidemiology, Management Gaps, and Future Directions: A Scientific Statement From the American Heart Association
doi : 10.1161/CIR.0000000000001019
Circulation. 2021;144:e193
